Background: International guidelines currently recommend the use of molecular testing in patients with advanced pancreatic cancer. The rate of actionable molecular alterations is low. The utility of molecular testing in patients with borderline resectable (BRPC) or locally advanced (LAPC) pancreatic cancer in real world clinical practice is unclear.
No takes yet. Share an insight, caveat, or question.
Farnes et al. (2024) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: